SFDCT / Dow Settlement Disease Criteria

Systemic Lupus Erythematosus (SLE) - Option 1
Do I Have A Case?
Expedited Release Checks Important Please Read
The Settlement Facility Dow Corning Trust has recently decided to send Expedited Release Payments ($2,000) to all claimants whose cases are idle.
The Dow Settlement criteria states that if you accept this payment you can NEVER apply for a disease claim in the future, even if you become sick.
If you receive one of these checks in the mail, please do not cash it until you speak with an attorney to discuss your potential claim.
Again, if you cash this check you have effectively settled your claim and can never get any additional money.
SFDCT Medical Criteria
Learn about the medical criteria that you will need to meet in order to submit a disease claim through the SFDCT Settlement.
Malar Rash: Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds.
Discoid Rash: Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions.
Photosensitivity: Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation.
Oral Ulcers: Oral or nasopharyngeal ulceration, usually painless, observed by a physician.
Arthritis: Nonerosive arthritis involving two or more peripheral joints, characterized by tenderness, swelling or effusion.
Serositis:
a.
Pleuritis --convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion, or
b.
Pericarditis --documented by ECG or rub or evidence of pericardial effusion.
Renal Disorder:
a.
Persistent proteinuria more than 0.5 g/day or greater than 3 + if quantitation not performed or
b.
Cellular casts -may be red cell, hemoglobin, granular, tubular, or mixed.
Neurologic Disorder:
a.
Seizures -in the absence of offending drugs or known metabolic derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance or
b.
Psychosis -in the absence of offending drugs or known metabolic derangements; e.g. uremia, ketoacidosis, or electrolyte imbalance.
Hematologic Disorder:
a.
Hemolytic anemia -with reticulocytosis or
b.
Leukopenia -less than 4000/mm total on two (2) or more occasions or
c.
Lymphopenia -less than 1500/mm on two (2) or more occasions or
d.
Thrombocytopenia -less than 100,000/mm in the absence of offending drugs.
Immunologic Disorder:
a.
Positive LE cell preparation or
b.
Anti-DNA -antibody to native DNA in abnormal titer or
c.
Anti-Sm -presence of antibody to Sm nuclear antigen or
d.
False positive serologic test for syphilis known to be positive for at least six (6) months and
e.
confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test.
Antinuclear Antibody: An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with drug-induced lupus syndrome.
A diagnosis of systemic lupus erythematosus (SLE) shall be made in accordance with 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus, 25 Arthritis and Rheumatism No. 11 (November 1982) adopted by the American College of Rheumatology. See Kelley, 4th ed. at 1037, Table 61-11: A diagnosis of lupus is made if four (4) of the eleven (11) manifestations listed in the table were present, either serially or simultaneously, during any interval of observations.
1.
2.
The application of the ACR diagnostic criteria is not intended to exclude from the compensation program individuals who present clinical symptoms or laboratory findings atypical of SLE but who nonetheless have a systemic lupus erythematosus-like disease, except that an individual will not be compensated in this category if her symptomology more closely resembles mixed connective tissue disease (MCTD), ACTO, or any other disease or condition defined below.
3.
The application of the ACR diagnostic criteria is not intended to exclude from the compensation program individuals who present clinical symptoms or laboratory findings atypical of SLE but who nonetheless have a systemic lupus erythematosus-like disease, except that an individual will not be compensated in this category if her symptomology more closely resembles mixed connective tissue disease (MCTD), ACTO, or any other disease or condition defined below.
a.
Death or total disability resulting from SLE or an SLE-like condition. An individual will be considered totally disabled based on either the functional capacity test set forth in Severity/Disability Category A for ACTD/ARS/NAC or severe renal involvement.
b.
SLE with major organ involvement defined as SLE with one (1) or more of the following - glomerulonephritis, central nervous system involvement (i.e. seizures or Lupus Psychosis), myocarditis, pneumonitis, thrombocytopenic purpura, hemolytic anemia (marked), severe granulocytopenia, mesenteric vasculitis. See Immunological Diseases, Max Samter, Ed. Table 56-6, at 1352.
c.
Non-major organ SLE requiring regular medical attention, including doctor visits and regular prescription medications. An individual is not excluded from this category for whom prescription medications are recommended but who, because of the side effects of those medications, chooses not to take them.
d.
Non-major organ SLE requiring little or no treatment. An individual will fall into this category if she is able to control her symptoms through the following kinds of conservative measures: over-the-counter medications, avoiding sun exposure, use of lotions for skin rashes, and increased rest periods.
727-397-9198 9am-5pm / Mon.-Thu.